SECTION 3
Two forces are increasing efficiency in precision oncology development. Recent advances in multi-omics and computational analytics are expediting the discovery and validation of biomarkers. Expanding clinical trials to regional and community sites is helping sponsors achieve faster enrollment times, more diverse patient populations, and the same high-quality trial data.
Contributing Experts
Amy Pace, ScD
Vice President, Biostatistics
Angela Hirst
Director, Site Alliance, Therapeutic Networks, Oncology
Angela Qu, M.D., Ph.D.
Senior Vice President, Translational Medicine, Global Head of Biomarkers & Genomic Medicine
Karen McIntyre
Vice President, Global Site Alliances, Launch Excellence
Matthew Gordon
Vice President, Real-World Evidence Strategy
Stacy Hurt, M.H.A., M.B.A.
Chief Patient Officer
Contributing Experts
Amy Pace, ScD
Vice President, Biostatistics
Angela Hirst
Director, Site Alliance, Therapeutic Networks, Oncology
Angela Qu, M.D., Ph.D.
Senior Vice President, Translational Medicine, Global Head of Biomarkers & Genomic Medicine
Karen McIntyre
Vice President, Global Site Alliances, Launch Excellence
Matthew Gordon
Vice President, Real-World Evidence Strategy
Stacy Hurt, M.H.A., M.B.A.
Chief Patient Officer
Stay current with novel thinking and actionable insights from our experts.
The vision of precision oncology—to treat each patient with the exact right medicine—is within reach yet still remote. We will move closer to the long-term vision by solving practical short-term problems and prioritizing innovation. At Parexel, we navigate multi-omics profiling, biomarkers, dose optimization, clinical trial site selection, companion diagnostics, regulatory strategy, and commercialization one challenge at a time while staying focused on improving the patient journey, our North Star.
Our oncology-focused patient advocates, scientists, statisticians, and former regulators are proud to partner with sponsors to advance precision oncology.